ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Big Drug Firms Exit Biotech Partnerships

by Lisa M. Jarvis
December 14, 2009 | APPEARED IN VOLUME 87, ISSUE 50

Three big pharma firms are ending biotech partnerships as they reassess their drug pipelines. After integrating Genentech, Roche has canceled deals with two partners, Actelion and Genmab. Actelion says it will continue to pursue development of ACT-12880, a selective S1P1 receptor agonist, as a treatment for psoriasis and multiple sclerosis. Genmab has not indicated the future of RG1507, a monoclonal antibody directed against the insulin-like growth factor-1 receptor. Meanwhile, Eli Lilly & Co. has returned to Isis Pharmaceuticals the rights to the anticancer drug ISIS-EIF4ERx, which has completed Phase I trials. And GlaxoSmithKline is returning to Cytokinetics the rights to GSK-923295, an inhibitor of centromere-associated protein E that is currently in Phase I trials for solid tumors.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment